<VariationArchive RecordType="classified" VariationID="12134" VariationName="SLC25A20, 110-BP DEL" VariationType="Deletion" Accession="VCV000012134" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-11-13" DateCreated="2019-08-09" MostRecentSubmission="2019-08-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="27173" VariationID="12134">
      <GeneList>
        <Gene Symbol="SLC25A20" FullName="solute carrier family 25 member 20" GeneID="788" HGNC_ID="HGNC:1421" Source="submitted" RelationshipType="asserted, but not computed">
          <Location>
            <CytogeneticLocation>3p21.31</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="48856926" stop="48898882" display_start="48856926" display_stop="48898882" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="48894355" stop="48936425" display_start="48894355" display_stop="48936425" Strand="-" />
          </Location>
          <OMIM>613698</OMIM>
        </Gene>
      </GeneList>
      <Name>SLC25A20, 110-BP DEL</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>3p21.31</CytogeneticLocation>
      </Location>
      <OtherNameList>
        <Name>110-BP DEL</Name>
      </OtherNameList>
      <XRefList>
        <XRef Type="Allelic variant" ID="613698.0003" DB="OMIM" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff could not provide HGVS expressions for allelic variant 613698.0003 because the paper by Huizing et al., 1998 (PubMed 9686371), did not include detailed sequence information.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="SLC25A20, 110-BP DEL AND Carnitine acylcarnitine translocase deficiency" Accession="RCV000012917" Version="3">
        <ClassifiedConditionList TraitSetID="3286">
          <ClassifiedCondition DB="MedGen" ID="C0342791">Carnitine acylcarnitine translocase deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1998-06-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="1998-06-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2019-08-09" MostRecentSubmission="2019-08-09">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">9686371</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3286" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10955" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Carnitine acylcarnitine translocase deficiency</ElementValue>
                <XRef ID="Carnitine-Acylcarnitine+Translocase+Deficiency/1115" DB="Genetic Alliance" />
                <XRef ID="238003000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CACTD</ElementValue>
                <XRef Type="MIM" ID="212138" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="1123" />
                <XRef ID="1123" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Carnitine-acylcarnitine translocase (CACT) is a critical component of the carnitine shuttle, which facilitates the transfer of long-chain fatty acylcarnitines across the inner mitochondrial membrane. CACT deficiency causes a defect in mitochondrial long-chain fatty acid ß-oxidation, with variable clinical severity. Severe neonatal-onset disease is most common, with symptoms evident within two days after birth; attenuated cases may present in the first months of life. Hyperammonemia and cardiac arrhythmia are prominent in early-onset disease, with high rates of cardiac arrest. Other clinical features are typical for disorders of long-chain fatty acid oxidation: poor feeding, lethargy, hypoketotic hypoglycemia, hypotonia, transaminitis, liver dysfunction with hepatomegaly, and rhabdomyolysis. Univentricular or biventricular hypertrophic cardiomyopathy, ranging from mild to severe, may respond to appropriate dietary and medical therapies. Hyperammonemia is difficult to treat and is an important determinant of long-term neurocognitive outcome. Affected individuals with early-onset disease typically experience brain injury at presentation, and have recurrent hyperammonemia leading to developmental delay / intellectual disability. Affected individuals with later-onset disease have milder symptoms and are less likely to experience recurrent hyperammonemia, allowing a better developmental outcome. Prompt treatment of the presenting episode to prevent hypoglycemic, hypoxic, or hyperammonemic brain injury may allow normal growth and development.</Attribute>
                <XRef ID="NBK582032" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">35862567</ID>
                <ID Source="BookShelf">NBK582032</ID>
              </Citation>
              <Citation Type="Position Statement" Abbrev="HGS Australasia, 2019">
                <URL>https://www.hgsa.org.au/documents/item/8694</URL>
                <CitationText>Policy: Recommendations for Screening for Specific Disorders</CitationText>
              </Citation>
              <XRef ID="159" DB="Orphanet" />
              <XRef ID="C0342791" DB="MedGen" />
              <XRef ID="MONDO:0008918" DB="MONDO" />
              <XRef Type="MIM" ID="212138" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="33158" SubmissionDate="2019-08-06" DateLastUpdated="2019-08-09" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="613698.0003_CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY" title="SLC25A20, 110-BP DEL_CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY" />
        <ClinVarAccession Accession="SCV000033158" DateUpdated="2019-08-09" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1998-06-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">For discussion of the 110-bp deletion (basepairs 671-680) in the SLC25A20 gene that was found in compound heterozygous state in sibs with carnitine-acylcarnitine translocase deficiency (CACTD; 212138) by Huizing et al. (1998), see 613698.0002.</Attribute>
              <Citation>
                <ID Source="PubMed">9686371</ID>
              </Citation>
              <XRef DB="OMIM" ID="212138" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A20" />
          </GeneList>
          <Name>SLC25A20, 110-BP DEL</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">110-BP DEL</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="613698.0003" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="33158" TraitType="Disease" MappingType="Name" MappingValue="CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY" MappingRef="Preferred">
        <MedGen CUI="C0342791" Name="Carnitine acylcarnitine translocase deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

